Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers

被引:25
作者
Ochoa, Dolores [1 ]
Prieto-Perez, Rocio [1 ]
Roman, Manuel [1 ]
Talegon, Maria [1 ]
Rivas, Angela [1 ]
Galicia, Ignacio [2 ]
Abad-Santos, Francisco [1 ,3 ]
Cabaleiro, Teresa [1 ,3 ]
机构
[1] Hosp Univ Princesa, Clin Pharmacol Serv, Inst Teofilo Hernando, Inst Invest Sanitaria Princesa IP, Madrid 28006, Spain
[2] Fdn Teofilo Hernando, Madrid 28049, Spain
[3] Inst Salud Carlos III, CIBERehd, Madrid 28029, Spain
关键词
CYP2C8; CYP2C9; ibuprofen; pharmacokinetics; polymorphisms; CYTOCHROME P4502C9 POLYMORPHISMS; IN-VITRO; FUNCTIONAL-CHARACTERIZATION; HEALTHY-VOLUNTEERS; METABOLISM; PHARMACODYNAMICS; GENOTYPES; ACID; (R)-IBUPROFEN; VARIABILITY;
D O I
10.2217/pgs.15.40
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aim: To evaluate the effect of polymorphisms in CYP2C9 and CYP2C8 and gender on the pharmacokinetics of the enantiomeric forms of ibuprofen. Materials & methods: 122 healthy volunteers were genotyped for polymorphisms in CY2C8 and CYP2C9 using real-time PCR. Results:CYP2C8 polymorphisms affected neither R- nor S-ibuprofen. CYP2C9*3 and CYP2C9*2 carriers had a lower S-ibuprofen clearance and a higher S-ibuprofen AUC and half-life. R-ibuprofen clearance was decreased in CYP2C9*3 carriers. Gender affected R-ibuprofen and S-ibuprofen pharmacokinetics. Multiple regression analysis showed that CYP2C9*2, CYP2C9*3 and gender were associated with S-ibuprofen clearance, but only CYP2C9*3 was associated with R-ibuprofen clearance. Conclusion: The pharmacokinetics of S-ibuprofen and R-ibuprofen is affected by CYP2C9 polymorphisms and gender. CYP2C8 polymorphisms do not have a significant role. Original submitted 6 February 2015; Revision submitted 1 April 2015
引用
收藏
页码:939 / 948
页数:10
相关论文
共 50 条
  • [41] Allele frequency distribution of CYP2C9*2 and CYP2C9*3 polymorphisms in six Mexican populations
    Castelan-Martinez, Osvaldo D.
    Hoyo-Vadillo, Carlos
    Sandoval-Garcia, Emmanuel
    Sandoval-Ramirez, Lucila
    Gonzalez-Ibarra, Miriam
    Solano-Solano, Gloria
    Gomez-Diaz, Rita A.
    Parra, Esteban J.
    Cruz, Miguel
    Valladares-Salgado, Adan
    [J]. GENE, 2013, 523 (02) : 167 - 172
  • [42] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    [J]. FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [43] The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
    Kobayashi, Mariko
    Takagi, Miho
    Fukumoto, Kyoko
    Kato, Ryuji
    Tanaka, Kazuhiko
    Ueno, Kazuyuki
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 115 - 119
  • [44] Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
    Adehin, Ayorinde
    Adeagbo, Babatunde A.
    Kennedy, Martin A.
    Bolaji, Oluseye O.
    Olugbade, Tiwalade A.
    Bolarinwa, Rahman A.
    Durosinmi, Muheez A.
    [J]. LEUKEMIA & LYMPHOMA, 2019, 60 (01) : 216 - 221
  • [45] CYP2C9 Genotype-DependentWarfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R-and S-Warfarin and Their Oxidative Metabolites
    Flora, Darcy R.
    Rettie, Allan E.
    Brundage, Richard C.
    Tracy, Timothy S.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (03) : 382 - 393
  • [46] Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam
    Bae, Jung-Woo
    Choi, Chang-Ik
    Jang, Choon-Gon
    Lee, Seok-Yong
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (04) : 550 - 555
  • [47] Polymorphisms in CYP1A2, CYP2C9 and ABCB1 affect agomelatine pharmacokinetics
    Saiz-Rodriguez, Miriam
    Ochoa, Dolores
    Belmonte, Carmen
    Roman, Manuel
    Vieira de Lara, Danilo
    Zubiaur, Pablo
    Koller, Dora
    Mejia, Gina
    Abad-Santos, Francisco
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (04) : 522 - 531
  • [48] The influences of CYP2C9*1/*3 genotype on the pharmacokinetics of zolpidem
    Byeon, Ji-Yeong
    Kim, Young-Hoon
    Kim, Se-Hyung
    Lee, Choong-Min
    Jung, Eui-Hyun
    Chae, Won-Ki
    Jang, Choon-Gon
    Lee, Seok-Yong
    Lee, Yun Jeong
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2018, 41 (09) : 931 - 936
  • [49] Preemptive Genotyping of CYP2C8 and CYP2C9 Allelic Variants Involved in NSAIDs Metabolism for Sickle Cell Disease Pain Management
    Jaja, Cheedy
    Bowman, Latanya
    Wells, Leigh
    Patel, Niren
    Xu, Hongyan
    Lyon, Matt
    Kutlar, Abdullah
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2015, 8 (04): : 272 - 280
  • [50] Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes
    Park, So-Young
    Phi-Hung Nguyen
    Kim, Gahyun
    Jang, Su-Nyeong
    Lee, Ga-Hyun
    Phuc, Nguyen Minh
    Wu, Zhexue
    Liu, Kwang-Hyeon
    [J]. PHARMACEUTICS, 2020, 12 (04)